Reuters logo
BRIEF-Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center
December 6, 2017 / 2:12 PM / 6 days ago

BRIEF-Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center

Dec 6 (Reuters) - Juno Therapeutics Inc:

* JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION

* JUNO THERAPEUTICS - THREE LICENSE DEALS TO ADVANCE PROGRAM IN MULTIPLE MYELOMA USING GAMMA SECRETASE INHIBITORS WITH BCMA-DIRECTED CAR T CELLS

* JUNO THERAPEUTICS INC - THROUGH ITS AGREEMENT WITH ELI LILLY AND COMPANY, JUNO WILL ACQUIRE A LICENSE TO GSI KNOWN AS LY3039478

* JUNO THERAPEUTICS- CO TO ALSO GAIN RIGHTS TO INTELLECTUAL PROPERTY WITHIN FIELD OF COMBINATIONS OF GSIS, BCMA-DIRECTED ENGINEERED T CELLS IN OTHER DEALS

* JUNO THERAPEUTICS INC - NO OTHER TERMS FROM THESE THREE TRANSACTIONS WERE DISCLOSED Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below